Electroconvulsive Therapy for Bipolar Disorder | NYU Langone Health
Doctors at NYU Langone may prescribe electroconvulsive therapy for adults with bipolar disorder that does not respond to other treatments.
Electroconvulsive Therapy for Depression | NYU Langone Health
Doctors at NYU Langone may prescribe electroconvulsive therapy for people with severe depression who have not responded to other treatments.
Electroconvulsive Therapy Program at Inpatient Psychiatry at Tisch Hospital | NYU Langone Health
The Electroconvulsive Therapy Program at NYU Langone’s Tisch Hospital provides inpatient and outpatient treatment and care.
Electronic cigarettes as a harm reduction strategy in people living with HIV/AIDS
People living with HIV/AIDS (PLWHA) are known to have exceptionally higher rate of cigarette smoking and very low quit rates compared to the general population. Although a primary rationale for conducting this study is reducing health disparities among PLWHA, there is a potential benefit of the proposed work from a prevention perspective given that combustible cigarette smoking is an independent risk factor for non-adherence to ART and may decrease the effectiveness of HAART (1-5). Smoking-related illnesses are leading causes of non-HIV/AIDS-related deaths among People Living with HIV/AIDS (PLWHA). (6) There are major yet unique barriers to combustible cigarette (CC) cessation among PLWHA.7? Additionally, FDA approved CC cessation medications have not been effective with this population. (8-11) Electronic cigarettes (E-cigarettes) could help people reduce the harm of CC through reductions in number of Cigarettes per Day (CPD) or quitting CC completely by addressing both nicotine and behavioral dependence. (12-14) A harm reduction approach may be more appropriate to use with PLWHA.15 This mixed-methods study’s purpose is to identify barriers and facilitators, as well as assess preliminary effectiveness of e-cigarettes as a harm reduction strategy among PLWHA.
Elizabeth Golden | NYU Langone Health
Elizabeth Golden is the executive vice president for communications, marketing, government and community affairs at NYU Langone.
Elucidating Neural Mechanisms and Sex Differences in Response to Mindfulness Based Stress Reduction in Generalized Anxiety Disorder
Mindfulness-Based Stress Reduction (MBSR) has demonstrated efficacy for Generalized Anxiety Disorder (GAD), yet there remains a major knowledge gap about its neural mechanisms. Neuroimaging studies thus far have mostly focused on the impact of MBSR on structural and resting-state brain changes, and these studies have been predominantly conducted in healthy participants. Core features of GAD, such as ruminative worry, represent dysfunctional emotion regulation strategies that increase bias towards future threat. MBSR success is associated with improved emotion regulation, enhanced attention to the present moment, and non-judgmental acceptance of internal and external cues. Our primary aim is to elucidate neural mechanisms that drive response to MBSR in patients with generalized anxiety disorder (GAD), and to examine the degree to which sex differences in MBSR response are explained by sex differences in these mechanisms. Our overarching hypothesis is that MBSR enhances ‘top-down’ learning and memory capacities that are broad and impact ‘top-down’ as well as ‘instinctual’ abilities (bottom-up) to regulate fear and emotions. We will first study the functional activation of brain regions associated with the fear extinction network (ventromedial prefrontal cortex (vmPFC), hippocampus, and amygdala) as a specific probe of the ‘instinctual’ type of emotion regulation. Second, we will use a novel analytic approach to examine large-scale functional connectivity as a marker of neural plasticity changes (pre- and post-MBSR) trial-by-trial during fear extinction learning across the entire brain, focusing analyses on the default mode network (DMN), frontoparietal network (FPN), and ventral attention network (VAN). Next, we will examine sex differences in MBSR-induced neural changes and their relationship to sex differences in clinical GAD response. Finally, we will use a novel statistical approach to explore whether baseline neural measures can predict MBSR-induced neural changes and clinical symptom reduction to identify likely MBSR responders. Participants will undergo a standardized 2-day fear conditioning and extinction paradigm in the fMRI scanner before and after MBSR or stress education (SE) with primary clinical outcomes at endpoint and 3 month follow-up. This study will deploy rigorous scientific methods with a time and attention control intervention to enable isolation of MBSR’s mechanistic impact on brain regions involved in emotion regulation and clinical response. The unique combination of a focus on a classic anxiety condition with established emotion regulation difficulties implicating target neural circuits, previously demonstrated MBSR efficacy, and sex differences with rigorous fMRI behavioral probes with novel analytic approaches ought to provide major new insights about MBSR mechanisms and sex considerations, moving towards precision medicine that could guide future treatment development research.
EMBER-4: A Randomized Open-Label Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+ HER2- Early Breast Cancer with an Increased Risk of Recurrence
EMBER-4 is a Phase 3 global, randomized, open-label study of adjuvant imlunestrant vs SOC adjuvant ET of physician’s choice in participants who have previously received 2 to 5 years of standard ET for ER+, HER2- EBC (Stages I-III) with an increased risk of recurrence. Eligible participants must have completed definitive locoregional therapy, received 2 to 5 years of standard adjuvant ET without disease recurrence, and must have an increased risk of recurrence based on clin-path features at diagnosis, as defined in the inclusion criteria (Protocol Section 5.1). Participants may have received (neo) adjuvant chemotherapy and/or targeted therapy with a CDK4/6- or PARP- inhibitor. Participants may not have had a gap of 6 consecutive months during the SOC ET treatment and should not have stopped SOC ET more than 6 months prior to randomization. The study will consist of a 28-day screening phase, followed by a 5-year treatment phase, and a 5-year posttreatment phase, which will include safety, efficacy, and survival follow-up assessments.Physician’s choice ET (tamoxifen or an AI) must be selected and documented for each participant prior to randomization. Participants will be randomized using the following stratification factors: 1. Time from start of initial adjuvant ET to initiation of study treatment (2 to =3 years vs >3 to 5 years)2. Received prior adjuvant CDK4/6 inhibitor treatment (yes vs no)3. Nodal status (=N2 vs N1 vs N0)a4. Menopausal status (pre-/peri-menopausal vs postmenopausal)b5. Region (North America/Europe vs Asia vs Other)
Embolization for Liver Cancer & Liver Metastases | NYU Langone Health
NYU Langone’s Perlmutter Cancer Center doctors may use embolization to deliver chemotherapy or radiation directly to liver tumors.
Embryo, Egg & Sperm Storage Fees | NYU Langone Health
Get information on embryo, egg, and sperm storage fees at the NYU Langone Fertility Center.
Emergency Care | NYU Langone Health
NYU Langone offers emergency and urgent care at a variety of locations in Manhattan and Brooklyn, as well as Virtual Urgent Care.